987 Can Disease Progression in Non-Alcoholic Steatohepatitis Be Stopped?

Copaci, I.; Mindrut, E.; Micu, L.; Hortopan, M.; Voiculescu, M

doi:10.1016/s0168-8278(09)60989-2

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one excluded study, published in Spanish, three patients were treated with UDCA for 1 year, with one showing ALT and AST normalization [ 17 ]. Another excluded study, from the Cochrane Library, showed that UDCA plus pentoxyphylline had significant effects on ALT normalization and hepatic inflammation improvement [ 18 ]. A third study showed that UDCA was more effective than gemfibrozil in improving biochemical parameters in patients with NASH patients [ 19 ].…”

Section: Resultsmentioning

confidence: 99%

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

et al. 2013

View full text Add to dashboard Cite

BackgroundNon-alcoholic steatohepatitis (NASH) is a condition that occurs during the progression of non-alcoholic fatty liver disease. Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH.MethodsWestern and Chinese databases were searched by independent investigators using appropriate MESH headings to identify randomized, controlled Western and Chinese clinical trials, published between January 1990 and October 2012, testing the effects of UDCA in patients with NASH. Patient characteristics and trial endpoints were analyzed, with quality assessment according to widely acknowledged criteria. P < 0.05 was defined as statistically significant in all trials.ResultsTwelve qualified randomized clinical trials, including six from China and involving 1160 subjects, were selected. Seven of these trials assessed the effects of UDCA Monotherapy, with the other five testing combinations of UDCA with vitamin E, polyene phosphatidylcholine, silymarin, glycyrrhizin and tiopronin. The duration of therapy ranged from 3 to 24 months, with two studies using high doses of UDCA (23–35 mg/kg/d). The average quality point was 2.69, and was significantly lower in articles from China than in those from Western countries (2.2 ± 0.4 vs. 3.8 ± 1.1, respectively, p < 0.05). UDCA Monotherapy significantly improved liver function in five studies and improved steatosis and fibrosis in two studies. All five studies assessing UDCA combination therapy showed significant improvements liver function, while two studies also improved steatosis and inflammation. One study of high-dose UDCA showed significant improvements in ALT, γGT and liver fibrosis, whereas the other study showed no significant change in ALT and liver pathology.ConclusionsUDCA therapy is effective in NASH, especially when combined with other drugs. However, the low quality of these studies and the heterogeneity of their results precluded further meta-analysis. Additional carefully designed clinical trials are needed, especially in China.

show abstract

Section: Resultsmentioning

confidence: 99%

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…В последующем развиваются хроническое персистирующее воспаление, апоптоз, некроз гепатоцитов. Это становится «вторым толчком» в патогенезе НАЖБП, оказывающим значительное влияние на течение болезни за счет интенсивности воспаления и фиброзирования в ткани печени [24].…”

unclassified

Non - alcoholic fatty liver disease and enteral insufficiency: comorbidity of their development

Сучкова

Vakhrushev

2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The article reflects current literature data on the epidemiology and risk factors of non - alcoholic fatty liver disease. An important aspect is the description of the modern views of combined lesions of the hepatobiliary tract and small intestine. Disorders of the intestinal microbiota play a special role in the development of non - alcoholic fatty liver disease. The value of enterohepatic circulation of bile acids in the development of intestinal and liver diseases was shown. It seems relevant to further study the comorbidity of the development of non - alcoholic fatty liver disease and enteropathy for the development of pathogenetically substantiated therapy.

show abstract

“…Stwierdzono poprawę w zakresie zmniejszenia zapalenia śródzrazikowego i zmniejszenia aktywności GGTP [23]. Badania porównawcze z zastosowaniem pentoksyfiliny i UDCA wskazały na korzystny wpływ jednoczesnego podawania tych preparatów (odpowiednio 1200 mg pro diae i 13 mg/kg m.c./dobę) w zakresie zmniejszenia aktywności AlAT, stężenia ferrytyny i zmian histopatologicznych w zaawansowanych przypadkach NASH [24].…”

unclassified

Ursodeoxycholic acid in liver diseases

Juszczyk¹

2012

View full text Add to dashboard Cite

show abstract

987 Can Disease Progression in Non-Alcoholic Steatohepatitis Be Stopped?

Cited by 4 publications

References 0 publications

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Non - alcoholic fatty liver disease and enteral insufficiency: comorbidity of their development

Ursodeoxycholic acid in liver diseases

Contact Info

Product

Resources

About